Literature DB >> 8696636

Compliance with hormonal treatment for prostate cancer.

A V Kaisary1.   

Abstract

Compliance is an important factor when choosing drug therapy for chronic illnesses such as prostate cancer. Antiandrogens can be used, either in combination with medical castration or as monotherapy, to treat prostate cancer. In selecting appropriate therapy, drug-related factors which might influence compliance need to be considered.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8696636

Source DB:  PubMed          Journal:  Br J Hosp Med        ISSN： 0007-1064


  4 in total

1.  Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study.

Authors:  Yoichi Arai; Hideyuki Akaza; Takashi Deguchi; Masato Fujisawa; Mikio Hayashi; Yoshihiko Hirao; Hiroshi Kanetake; Seiji Naito; Mikio Namiki; Masaaki Tachibana; Michiyuki Usami; Yasuo Ohashi
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-20       Impact factor: 4.553

Review 2.  Primary hormone therapy for locally advanced prostate cancer.

Authors:  Gregory P Swanson
Journal:  Curr Urol Rep       Date:  2006-05       Impact factor: 2.862

3.  Controversies in the management of advanced prostate cancer.

Authors:  C J Tyrrell
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

4.  Investigation of the In Vitro and In Vivo efficiency of RM-532-105, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor models.

Authors:  Lucie Carolle Kenmogne; Jenny Roy; René Maltais; Mélanie Rouleau; Bertrand Neveu; Frédéric Pouliot; Donald Poirier
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.